Reliance To Create A Price Disruption In The Genome Testing Market

Mukesh Ambani’s group is getting into genetic mapping, following the trend created by US startups like 23andMe. At US$145, the test will be more affordable than currently available options in India’s growing consumer market.

Strand Life Sciences developed the product; and in 2021, Reliance Industries acquired about 80% of the Bengaluru-based firm.

The genome test, which is about 86% cheaper than other offerings available locally, can reveal a person’s predisposition to cancers, cardiac and neuro-degenerative ailments as well as identify inherited genetic disorders, he said.

GenomeTesting #RelianceIndustries #MukeshAmbani

Related articles

WhatsApp Image 2023-08-25 at 12.29.19
The esteemed IT services company is thrilled to announce its exciting three-year partnership with the globally renowned tennis sensation, Rafael Nadal!